Halozyme CEO Helen Torley sells 60,000 shares

Q: How many HALO shares did Helen Torley sell?

Helen Torley sold 60,000 common shares across October 6, 7 and 8, 2026. Reported weighted-average prices included 2,300 shares at $107.9020 on October 6, 8,600 at $111.0310 on October 7, and 11,900 at $109.9950 on October 8.

Q: When were Helen Torley’s HALO options granted, and how did they vest?

The options were granted February 14, 2018 and were exercisable over a four-year period: 25% after 12 months, then 1/48th of the option shares each month thereafter. Their reported expiration date is February 14, 2028.

The option exercises and sales were made under a written Rule 10b5-1 plan adopted December 3, 2025.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

HALO’s President and CEO Helen Torley exercised options for 20,000 common shares on each of October 6, 7 and 8, 2026, at an exercise price of $18.4100 per share, acquiring 60,000 shares in total. On those same dates, she sold 60,000 common shares; reported weighted-average sale prices included 2,300 shares at $107.9020 on October 6, 8,600 at $111.0310 on October 7, and 11,900 at $109.9950 on October 8. The exercises and sales were made under a written Rule 10b5-1 trading plan adopted December 3, 2025. The options were granted February 14, 2018, and their reported expiration date is February 14, 2028.

Insider Trade Summary 10b5-1

Exercise and Sale: 60,000 shares ($5.51M approx. pre-tax spread)

Exercise and Sale 18 txns

Insider Torley Helen

Role PRESIDENT AND CEO

Sold 60,000 shs ($6.61M)

Approx. gross sale proceeds $6.61M

Approx. exercise cost $1.10M

Approx. pre-tax spread $5.51M

Type	Security	Shares	Price	Value
Exercise	Option to Purchase Common Stock ^{F1, F13}	20,000	$18.41	$368K
Exercise	Common Stock ^F1	20,000	$18.41	$368K
Sale	Common Stock ^{F1, F10}	4,810	$108.179	$520K
Sale	Common Stock ^{F1, F11}	3,090	$108.908	$337K
Sale	Common Stock ^{F1, F12}	11,900	$109.995	$1.31M
Sale	Common Stock ^F1	200	$110.51	$22K
Exercise	Option to Purchase Common Stock ^{F1, F13}	20,000	$18.41	$368K
Exercise	Common Stock ^F1	20,000	$18.41	$368K
Sale	Common Stock ^{F1, F6}	8,600	$111.031	$955K
Sale	Common Stock ^{F1, F7}	10,300	$111.839	$1.15M
Sale	Common Stock ^{F1, F8}	900	$112.78	$102K
Sale	Common Stock ^{F1, F9}	200	$113.693	$23K
Exercise	Option to Purchase Common Stock ^{F1, F13}	20,000	$18.41	$368K
Exercise	Common Stock ^F1	20,000	$18.41	$368K
Sale	Common Stock ^{F1, F2}	2,300	$107.902	$248K
Sale	Common Stock ^{F1, F3}	6,000	$109.334	$656K
Sale	Common Stock ^{F1, F4}	9,920	$109.891	$1.09M
Sale	Common Stock ^{F1, F5}	1,780	$110.812	$197K

Holdings After Transaction: Option to Purchase Common Stock — 21,552 contracts (Direct); Common Stock — 767,780 shares (Direct)

Footnotes (13)

F1. The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028.
F2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.480 to $108.290. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.530 to $109.520. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4. Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.530 to $110.510. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5. Represents a weighted average sales price per share. The shares were sold at prices ranging from $110.530 to $111.210. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6. Represents a weighted average sales price per share. The shares were sold at prices ranging from $110.360 to $111.350. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F7. Represents a weighted average sales price per share. The shares were sold at prices ranging from $111.380 to $112.360. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F8. Represents a weighted average sales price per share. The shares were sold at prices ranging from $112.400 to $113.190. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F9. Represents a weighted average sales price per share. The shares were sold at prices ranging from $113.590 to $113.860. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F10. Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.480 to $108.475. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F11. Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.480 to $109.470. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F12. Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.510 to $110.500. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F13. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018.

Key Figures

Options exercised: 60,000 shares Common shares sold: 60,000 shares Exercise price: $18.4100 per share +4 more

7 metrics

Options exercised 60,000 shares Across October 6–8, 2026

Common shares sold 60,000 shares Across October 6–8, 2026

Exercise price $18.4100 per share Options exercised October 6–8, 2026

Weighted-average sale price $107.9020 per share 2,300 shares sold October 6, 2026

Weighted-average sale price $111.0310 per share 8,600 shares sold October 7, 2026

Weighted-average sale price $109.9950 per share 11,900 shares sold October 8, 2026

Option expiration date February 14, 2028 Options reported as exercised

Key Terms

Rule 10b5-1, weighted average sales price, ten-year term

3 terms

Rule 10b5-1 regulatory

"written trading plan adopted by the Reporting Person on December 3, 2025"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

weighted average sales price financial

"Represents a weighted average sales price per share"

ten-year term financial

"stock options with a ten-year term expiring in February 2028"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many HALO shares did Helen Torley sell?

Helen Torley sold 60,000 common shares across October 6, 7 and 8, 2026. Reported weighted-average prices included 2,300 shares at $107.9020 on October 6, 8,600 at $111.0310 on October 7, and 11,900 at $109.9950 on October 8.

When were Helen Torley’s HALO options granted, and how did they vest?

The options were granted February 14, 2018 and were exercisable over a four-year period: 25% after 12 months, then 1/48th of the option shares each month thereafter. Their reported expiration date is February 14, 2028.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/08/2026 - 07:56 PM Accepted by SEC EDGAR 10/08/2026 - 07:56 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Torley Helen

(Last)

(First)

(Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO

CALIFORNIA

92130

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	PRESIDENT AND CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/06/2026		M⁽¹⁾		20,000	A	$18.41	787,780	D
Common Stock	10/06/2026		S⁽¹⁾		2,300	D	$107.902⁽²⁾	785,480	D
Common Stock	10/06/2026		S⁽¹⁾		6,000	D	$109.334⁽³⁾	779,480	D
Common Stock	10/06/2026		S⁽¹⁾		9,920	D	$109.891⁽⁴⁾	769,560	D
Common Stock	10/06/2026		S⁽¹⁾		1,780	D	$110.812⁽⁵⁾	767,780	D
Common Stock	10/07/2026		M⁽¹⁾		20,000	A	$18.41	787,780	D
Common Stock	10/07/2026		S⁽¹⁾		8,600	D	$111.031⁽⁶⁾	779,180	D
Common Stock	10/07/2026		S⁽¹⁾		10,300	D	$111.839⁽⁷⁾	768,880	D
Common Stock	10/07/2026		S⁽¹⁾		900	D	$112.78⁽⁸⁾	767,980	D
Common Stock	10/07/2026		S⁽¹⁾		200	D	$113.693⁽⁹⁾	767,780	D
Common Stock	10/08/2026		M⁽¹⁾		20,000	A	$18.41	787,780	D
Common Stock	10/08/2026		S⁽¹⁾		4,810	D	$108.179⁽¹⁰⁾	782,970	D
Common Stock	10/08/2026		S⁽¹⁾		3,090	D	$108.908⁽¹¹⁾	779,880	D
Common Stock	10/08/2026		S⁽¹⁾		11,900	D	$109.995⁽¹²⁾	767,980	D
Common Stock	10/08/2026		S⁽¹⁾		200	D	$110.51	767,780	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Option to Purchase Common Stock	$18.41	10/06/2026		M⁽¹⁾			20,000	⁽¹³⁾	02/14/2028	Common Stock	20,000	$18.41	61,552	D
Option to Purchase Common Stock	$18.41	10/07/2026		M⁽¹⁾			20,000	⁽¹³⁾	02/14/2028	Common Stock	20,000	$18.41	41,552	D
Option to Purchase Common Stock	$18.41	10/08/2026		M⁽¹⁾			20,000	⁽¹³⁾	02/14/2028	Common Stock	20,000	$18.41	21,552	D

Explanation of Responses:

1. The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028.

2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.480 to $108.290. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.530 to $109.520. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

4. Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.530 to $110.510. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

5. Represents a weighted average sales price per share. The shares were sold at prices ranging from $110.530 to $111.210. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

6. Represents a weighted average sales price per share. The shares were sold at prices ranging from $110.360 to $111.350. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

7. Represents a weighted average sales price per share. The shares were sold at prices ranging from $111.380 to $112.360. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

8. Represents a weighted average sales price per share. The shares were sold at prices ranging from $112.400 to $113.190. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

9. Represents a weighted average sales price per share. The shares were sold at prices ranging from $113.590 to $113.860. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

10. Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.480 to $108.475. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

11. Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.480 to $109.470. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

12. Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.510 to $110.500. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

13. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018.

Remarks:

	/s/ James R. Oehler, Attorney-in-Fact	10/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR